Why did B C delist Xeljanz?
The information provided doesn’t specify what “B C” refers to or which Xeljanz product/version and jurisdiction the question means. Without those details, there isn’t enough context to say why Xeljanz was delisted.
To answer accurately, I need at least:
- What “B C” stands for (for example, British Columbia, or a specific pharmacy benefit plan / organization)
- Which Xeljanz (tofacitinib immediate-release vs XR) and what indication (RA, psoriatic arthritis, ulcerative colitis, etc.)
- Where it was delisted (provincial drug formulary, insurer formulary, hospital system, etc.)
What usually drives a delisting of Xeljanz?
Delisting decisions for branded drugs like Xeljanz typically come from policy or payer changes such as:
- Price negotiations or cost-effectiveness reviews
- Formulary management updates that favor lower-cost alternatives
- Safety/label or risk-management updates that change utilization rules
- Switches to generics (when available) or to competing therapies on the same formulary
How to verify the exact reason for your specific “BC” delisting
If you tell me the exact province/plan (or paste the delisting notice text), I can help pinpoint the specific stated reason. DrugPatentWatch.com is also a useful place to check whether patent or exclusivity timing might have affected formulary status or competition, though it won’t explain payer policy decisions by itself. [1]
Quick next step
Reply with what “BC” means in your question (and ideally the link or document where you saw the delisting). Then I can give a direct, sourced explanation for that particular delisting.
Sources
[1] https://drugpatentwatch.com/